Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...

Health authorities in England on Wednesday announced the rollout of a world first vaccine program for gonorrhea, amid record ...

With antibiotic-resistant gonorrhea on the rise, the vaccine could provide a way to prevent the disease from spreading.

A vaccine targeting gonorrhea will soon be rolled out on the NHS. This will make England and Wales the first two countries in ...

Debiopharm initially received funding from CARB-X in 2017 for pre-clinical development of Debio1453, which inhibits an ...

Urinary tract infections are common and unpleasant, but a research team at Vanderbilt University has developed a ...

“Debio 1453 represents an approach to resistance targeting that ... to offer a durable solution to treating gonorrhea, for which all but one antibiotic has been rendered ineffective,” said ...

Gonorrhea can also be transmitted from a ... About CARB-X CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting ...

Antibiotics used to treat gonorrhea are chosen based on the rate of antibiotic resistance (when bacteria develop ways that make it harder for antibiotics to kill them) in the United States and ...

The Swiss drugmaker says the safety and efficacy of zosurabalpin will be investigated in a study involving 400 patients with ...